Discriminative effects of cyclazocine in the squirrel monkey
- PMID: 417173
Discriminative effects of cyclazocine in the squirrel monkey
Abstract
In order to characterize the discriminative stimulus properties of cyclazocine squirrel monkeys were trained to discriminate between intramuscular injections of 0.1 mg/kg of cyclazocine and drug vehicle in a discrete-trial avoidance paradigm in which a response on one of two levers would prevent or terminate the delivery of a mild electric shock to the tail. Behavior was considered to be under stimulus control when the monkeys completed at least 22 trials of a 25-trial session on the appropriate choice lever after they received cyclazocine or vehicle. Stimulus generalization (i.e., dose-response) curves were then determined for a variety of drugs over a broad range of doses. The following analgesics with narcotic antagonist properties produced stimulus control of behavior comparable to that produced by 0.1 mg/kg of cyclazocine: ketocyclazocine (0.1 mg/kg), butorphanol (1.0 mg/kg), oxilorphan (3.0 mg/kg) and levallorphan (3.0 mg/kg). Time course experiments revealed that the duration of complete stimulus control was relatively short: 1 hour after 0.1 mg/kg of cyclazocine and 3.0 mg/kg of oxilorphan and 0.5 hour after 0.1 mg/kg of ketocyclazocine. Naloxone produced a dose-related antagonism of the stimulus control by cyclazocine and butorphanol which was complete at 1.0 mg/kg. In contrast, as much as 10 mg/kg of naloxone only partially blocked stimulus control by ketocyclazocine and failed to modify stimulus control by oxilorphan and levallorphan. The monkeys showed partial generalization to other drugs with activity as narcotic agonists, antagonists or both (e.g., morphine, naloxone, pentazocine, nalbuphine, nalmexone and nalorphine), but little or no generalization to the nonopioid psychoactive drugs, d-amphetamine, mescaline, pentobarbital and scopolamine. This discrimination paradigm appears to have potential as a model for the quantitative assessment of the discriminative stimulus properties of narcotic antagonist analgesics.
Similar articles
-
Further evaluation of the discriminative effects of morphine in the rat.J Pharmacol Exp Ther. 1977 Apr;201(1):55-66. J Pharmacol Exp Ther. 1977. PMID: 15104
-
Discriminative stimulus effects of the opioid antagonist diprenorphine in the squirrel monkey.J Pharmacol Exp Ther. 1986 May;237(2):437-44. J Pharmacol Exp Ther. 1986. PMID: 3009783
-
Discriminative effects of morphine in the squirrel monkey.J Pharmacol Exp Ther. 1977 Apr;201(1):67-75. J Pharmacol Exp Ther. 1977. PMID: 15105
-
Limitations on the antagonistic actions of opioid antagonists.Fed Proc. 1982 May;41(7):2333-8. Fed Proc. 1982. PMID: 7042396 Review.
-
Measuring naloxone antagonism of discriminative opioid stimulus.Fed Proc. 1982 May;41(7):2319-22. Fed Proc. 1982. PMID: 7042395 Review.
Cited by
-
Three-choice drug discrimination: phencyclidine-like stimulus effects of opioids.Psychopharmacology (Berl). 1983;80(1):1-9. doi: 10.1007/BF00427484. Psychopharmacology (Berl). 1983. PMID: 6408661
-
Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions.Curr Top Behav Neurosci. 2018;39:175-192. doi: 10.1007/7854_2016_9. Curr Top Behav Neurosci. 2018. PMID: 27225498 Review.
-
Discriminative stimulus effects of spiradoline, a kappa-opioid agonist.Psychopharmacology (Berl). 1991;105(4):447-52. doi: 10.1007/BF02244362. Psychopharmacology (Berl). 1991. PMID: 1663252
-
Butorphanol: a review of its pharmacological properties and therapeutic efficacy.Drugs. 1978 Dec;16(6):473-505. doi: 10.2165/00003495-197816060-00001. Drugs. 1978. PMID: 365510 Review. No abstract available.
-
Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy.Drugs. 1983 Sep;26(3):191-211. doi: 10.2165/00003495-198326030-00002. Drugs. 1983. PMID: 6137354 Review.